HBP:CC - Helix BioPharma Corp. receives approval for the Extension of Annual General and Special Meeting to Seek Approval of Asset Acquisitions and Proposed Financing
(TheNewswire)
March 3, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT:“HBP0”) (“ Helix ” or the“ Company ”), a clinical-stage oncology company shaping a near futurewhere today’s hard-to-treat cancers are vincible, announces that, further to its news release dated February21, 2025, the Annual General and Special Meeting (the “ Meeting ”) for theyear ended July 31, 2024 has been extended to March 26, 2025 toprovide additional time to seek shareholder approval with respect toits proposed asset acquisitions from Laevoroc Immunology AG andLaevoroc Chemotherapy AG (the “ Asset Acquisitions ”), as well as a proposed financing utilizing a draw-downsubscription facility structure.
The Company applied to the Ontario Superior Court ofJustice for an order under section 133(3) of the Canada Business Corporations Act permitting it to hold the Meeting by March 26,2025. The application was approved on Wednesday, February 26, 2025.
The Notice of Meeting, Management Information Circular,Financial Statements Request Form, Form of Proxy and VotingInstruction Form (the “ Meeting Materials ”) have been mailed toshareholders and were posted on the Company’s profile on SEDAR+ atwww.sedarplus.ca on February 24, 2025.
Shareholders of record as of January 31, 2025, areentitled to vote their shares of the Company at the Meeting. TheCompany encourages its shareholders to vote in advance of the Meetingusing the instructions on the Voting Instruction Form or the Form ofProxy that will be mailed to them with the Meeting Materials.Shareholders are reminded that proxies must be received by 10 a.m.(EST) on March 24, 2025.
For more information, pleasecontact:
Helix BioPharma Corp.
Bay Adelaide Centre - North Tower
40 Temperance Street, Suite 2
Toronto, ON M5H 0B4
Tel: 604-428-7050
Jacek Antas, Director
About Helix BioPharma Corp.
Helix BioPharma Corp. is an oncology company shaping anear future where today’s hard-to-treat cancers are made vincible bynovel therapies that rise to the challenge. The Company innovates fromstrength to tackle cancer’s biggest, most urgent challenges with adiverse pipeline of drug candidates with great potential and a headstart, honed into first- and best-in-class oncology medicines. Itspipeline is spearheaded by a clinical-stage proprietary technologyplatform of bio- conjugates that score withprecision against prevalent CEACAM6-expressing solid tumours. Its leadcandidate, Tumour Defence Breaker TM L-DOS47, is aclinical-stage antibody-enzyme conjugate (AEC) that neutralizes themicroenvironment of common, hard-to-treat solid tumours, taking thebrakes off anti-cancer immunity and delivering a game-changing assistto today’s front-running anti-cancer therapies. L-DOS47 hascompleted Phase Ib studies in non-small cell lung cancer (NSCLC), withnovel strategically designed bi-specific ADCs targeting CEACAM6 indiscovery. Helix is listed on the TSX under thesymbol “HBP”, on OTC PINK under the symbol “HBPCD” and on FWBunder the symbol “HBP0”.
Forward-Looking Statements and Risksand Uncertainties
This news release containsforward-looking statements and information (collectively, “forwardlooking statements”) within the meaning of applicable Canadiansecurities laws. Forward-looking statements are statements andinformation that are not historical facts but instead includestatements regarding plans, goals, objectives, intentions andexpectations with respect to the closing of the Asset Acquisitions,the proposed financing, the date of the court application and the dateof the Meeting, the ability of the Company to obtain an order from theOntario Superior Court of Justice to extend the Meeting, and theCompany’s future business, operations, research and development.Forward-looking statements can further be identified by the use offorward-looking terminology such as “will”, “plans”,“expects”, or the negative thereof or any other variations thereonor comparable terminology referring to future events or results, orthat events or conditions “will”, “may”, “could”, or“should” occur or be achieved, or comparable terminology referringto future events or results. Forward-looking statements are statementsabout the future and are inherently uncertain and are necessarilybased upon a number of estimates and assumptions that are alsouncertain. Although the Company believes that the expectationsreflected in such forward-looking statements are reasonable, suchstatements involve risks and uncertainties, and undue reliance shouldnot be placed on such statements. Forward-looking statements areintended to provide information about management’s current plans andexpectations regarding future operations and may not be appropriatefor other purposes. Certain material factors, estimates or assumptionshave been applied in making forward-looking statements in this newsrelease. The Company’s actual results could differ materially fromthose anticipated in the forward-looking statements contained in thisnews release as a result of numerous known and unknown risks anduncertainties, including the risk factors discussed in the Company’scontinuous disclosure record filed under the Company’s profile onSEDAR+ at www.sedarplus.ca from time to time. Forward-lookingstatements and information are based on the beliefs, assumptions,opinions and expectations of Helix’s management on the date of thisnew release, and the Company does not assume any obligation to updateany forward-looking statement or information should those beliefs,assumptions, opinions or expectations, or other circumstances change,except as required.
Copyright (c) 2025 TheNewswire - All rights reserved.